Oxford Biomedica (otc) ( (OXBDF) ) has released its Q4 earnings. Here is a breakdown of the information Oxford Biomedica (otc) presented to its investors.
Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, known for its expertise in viral vector development and manufacturing. The company has facilities in the UK, US, and France, and collaborates with leading pharmaceutical and biotechnology companies to deliver innovative therapies.
In its latest earnings report for the year ended December 31, 2024, Oxford Biomedica reported a strong financial performance, with a 44% increase in total revenues to £128.8 million and an 81% organic growth rate. The company achieved an operating EBITDA profit in the second half of 2024, reflecting effective execution of its multi-vector, multi-site strategy.
Key financial highlights include a significant improvement in operating EBITDA loss, narrowing to £15.3 million from £52.8 million in 2023, and a contracted value of client orders increasing by 35% to approximately £186 million. The acquisition of ABL Europe, now OXB France, expanded the company’s manufacturing capabilities, contributing £11.5 million to revenue. The company also increased its ownership in OXB US LLC to 90%.
Oxford Biomedica’s strategic focus on expanding its viral vector platforms and technologies, including the launch of the inAAVate™ platform, has positioned it well for future growth. The company aims to achieve a revenue CAGR of more than 35% from 2023 to 2026 and expects to reach operating EBITDA profitability in 2025.
Looking ahead, Oxford Biomedica is confident in its ability to capitalize on the growing cell and gene therapy market, with plans to maintain its revenue growth trajectory and achieve sustainable profitability. The company’s management remains focused on operational excellence, client-centric innovation, and expanding its global presence.